empty
 
 
rs
Search
Podrška
Trenutno otvaranje računa
Trgovačka platforma
Depozit/Povlačenje
Search
Za početnike Za trgovce Za partnere Idi na pauzu About InstaSpot
rs
#ACB Nazad na listu instrumenata #AMGN

Menjač valuta

Alnylam Pharmaceuticals Inc.
240.1 USD
09 Jan 2025 18:15
Promena cene (% chg)
$0
(0%)
Cena prethodnog zatvaranja
Cena prethodnog zatvaranja

Cena zatvaranja prethodnog dana.
$240.1
Otvaranje
Otvaranje

Cena na otvaranju.
$234.37
Dnevni maksimum
Dnevni maksimum

Najviša cena tokom poslednjeg dana trgovine.
$240.1
Dnevni minimum
Dnevni minimum

Najniža cena tokom poslednjeg dana trgovine
$240.1
Maksimum u 52 nedelje
Maksimum u 52 nedelje

Opseg najviših cena u poslednje 52 nedelje
$240.1
Minimum u 52 nedelje
Minimum u 52 nedelje

Opseg najnižinih cena u poslednje 52 nedelje
$234
Preuzmi arhivu
Buy
240.1
Sell
240.1
Otvori grafikon za pregled na celom ekranu
Buy
240.1
Sell
240.1
Preuzmi arhivu
Otvori grafikon za pregled na celom ekranu

Alnylam Pharmaceuticals Inc. About company

Alnylam Pharmaceuticals Inc. is an American biopharmaceutical company, founded in 2002. The firm is mainly involved in the research and development of drugs for treating genetic disorders.

In 2016, Alnylam Pharmaceuticals Inc. was added to the Forbes list of the world’s 100 most innovative growth companies.

This year, the market capitalization of Alnylam Pharmaceuticals Inc. totals $17.65 billion. In 2021, it raised revenue of $844.29 million. In the first six months of 2022, the company earned as much as $224.82 million.

Alnylam Pharmaceuticals Inc.’s shares and factors shaping their value

The company has been listed on the NASDAQ exchange since 2004 under the ALNY ticker. Its share value currently totals $200-205. Over the past 12 months, ALNY has fluctuated in the range of $117 to $236.

When trading the firm’s stock, you should pay attention to the following factors:

  • The company has a heavy dependence on the state of the healthcare sector as a whole. Thus, new COVID outbreaks have a negative influence on its revenue growth;
  • The company occasionally introduces new drugs to the market, conducting clinical and laboratory trials and publishing the results beforehand;
  • Constantly growing revenues are the firm’s advantage;
  • Enough own funds to finance projects without the need to additionally issue securities.

Ne možete da razgovarate sada?
Postavite pitanje kroz ćaskanje.